Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL624112 | 0.94 | MPI (0.37) | MPIALDH1A1 | |
| SCHEMBL419463 | 0.94 | MPI (0.37) | MPIALDH1A1 | |
| Bicarbonate SCHEMBL8384988 | 0.92 | MPI (0.36) | MPIALDH1A1 | |
| Bicarbonate SCHEMBL8384375 | 0.92 | MPI (0.36) | MPIALDH1A1 | |
| SCHEMBL1032576 | 0.82 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL7070578 | 0.82 | MPI (0.37) | MPIALDH1A1 | |
| SCHEMBL1257819 | 0.82 | MPI (0.37) | MPI | |
| SCHEMBL7068623 | 0.82 | MPI (0.37) | MPIALDH1A1 | |
| SCHEMBL7066959 | 0.82 | MPI (0.37) | MPIALDH1A1 | |
| SCHEMBL2781260 | 0.82 | MPI (0.37) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807440-B1 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIV KANSAS (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2438078-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2012-04-11 | — | — | EP | disclosed |
| US-7960353-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | US | disclosed |
| WO-2011041593-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | UNIVERSITY OF KANSAS (US) | 2011-04-07 | — | — | WO | disclosed |
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | UNIVERSITY OF KANSAS (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | UNIVERSITY OF KANSAS (US) | 2010-02-25 | — | — | US | disclosed |
| US-7622451-B2 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | UNIVERSITY OF KANSAS (US) | 2009-11-24 | — | — | US | disclosed |
| US-7608594-B2 | Novobiocin analogues as anticancer agents | UNIVERSITY OF KANSAS (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-22 | — | — | US | disclosed |
| EP-1807440-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | The University of Kansas (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-07 | — | — | US | disclosed |
| WO-2006050501-A2 | NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS | UNIVERSITY OF KANSAS (US) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105630-A1 | NOVOBIOCIN ANALOGUES AS NEUROPROTECTIVE AGENTS AND IN THE TREATMENT OF AUTOIMMUNE DISORDERS | SSB, IAPP, NLN | MPI 2961/4885ALDH1A1 4309/4885 |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | MPI 1930/4885ALDH1A1 3407/4885 |
| US-20070270452-A1 | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders | SSB, IAPP, NLN | MPI 2961/4885ALDH1A1 4309/4885 |
| US-20060199776-A1 | Novobiocin analogues as anticancer agents | HSP90B1, HSP90AB2P, HSP90AB1 | MPI 1086/4885ALDH1A1 2718/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | MPI 268/4885ALDH1A1 3066/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | MPI 2374/4885ALDH1A1 4519/4885 |
| US-20110082098-A1 | NOVOBIOCIN ANALOGUES AND TREATMENT OF POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, HSP90B1 | MPI 4320/4885ALDH1A1 4382/4885 |
| US-20100048882-A1 | Novobiocin Analogues as Anticancer Agents | HSP90B1, HSP90AB2P, HSP90AB1 | MPI 1086/4885ALDH1A1 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.